Purpose Our understanding of thyroid-associated ophthalmopathy (TAO, AKA Graves'
orbitopathy, thyroid eye disease) has advanced substantially, since one of us (TJS) wrote …

Background and Objectives Corticosteroids are often empirically used to treat idiosyncratic
hepatotoxicity with severe features. Interestingly, intravenous methylprednisolone (MP) is …

Abstract β‐Catenin, the downstream effector of the Wnt signaling, plays important roles in
hepatic development, regeneration, and tumorigenesis. However, its role at hepatocyte …

Context Thyroid eye disease (TED), a vision-threatening and disfiguring autoimmune
process, has thwarted our efforts to understand its pathogenesis and develop effective and …

Background: A recent clinical trial has shown a beneficial effect of the antioxidant agent
selenium in Graves' orbitopathy (GO). In order to shed light on the cellular mechanisms on …

The outcomes of hepatitis E virus (HEV) infection are diverse, ranging from asymptomatic
carrier, self‐limiting acute infection, and fulminant hepatitis to persistent infection. This is …

Purpose The dual antiproliferative mechanism of mycophenolate appears to be beneficial in
Graves' orbitopathy (GO). Methods Safety data from the two published mycophenolate trials …

Objective Oxidative stress is involved in the pathogenesis of Graves' orbitopathy (GO) and
an antioxidant approach has been advocated for GO treatment. Here, we investigated the …

Objectives High‐dose pulsed methylprednisolone‐related liver injury cases have been
reported in the literature, but a prospective study in patients with multiple sclerosis (MS) has …

Objectives The current first‐line treatment for management of active thyroid eye disease
(TED) is high‐dose intravenous corticosteroids, which have the potential for serious adverse …